Plus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Houston, TX, March 19, 2025 – Plus Therapeutics, Inc., a pioneering clinical-stage pharmaceutical company specializing in the development of targeted radiotherapeutics and advanced platform technologies for central nervous system (CNS) cancers, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2024. The Company will make this announcement after the market closes on Thursday, March 27, 2025.
Conference Call and Webcast Details
Following the financial results release, Plus Therapeutics’ management team will conduct a conference call and webcast to discuss the quarterly and annual results in greater detail. The conference call is scheduled for 5:00 p.m. Eastern Time on March 27, 2025. Interested parties can participate in the call by dialing 1-877-407-8035 (domestic) or +1-201-689-8263 (international). The conference ID number is 13728552. A live webcast of the call will be available on the Investor Relations section of the Company’s website at
Impact on Individual Investors
The release of Plus Therapeutics’ fourth quarter and full year 2024 financial results and subsequent conference call will provide investors with valuable insights into the Company’s financial health and operational progress. This information could potentially influence investment decisions, as it may reveal key developments, trends, or financial performance indicators that could impact the stock price. It is essential for investors to closely monitor the Company’s financial performance and stay informed about any potential news or developments that could affect their investment.
Global Implications
Beyond the immediate impact on individual investors, Plus Therapeutics’ financial results and updates on its CNS cancer research could have broader implications for the pharmaceutical industry and the healthcare sector as a whole. The Company’s innovative approach to targeted radiotherapeutics and advanced platform technologies could pave the way for new treatments and therapies for various types of CNS cancers. This could lead to advancements in cancer care and potentially improve outcomes for patients. Additionally, the success of Plus Therapeutics could inspire further investment in research and development within the field, driving innovation and progress in the fight against CNS cancers.
Conclusion
On March 27, 2025, Plus Therapeutics, Inc. will report its fourth quarter and full year 2024 financial results, followed by a conference call and webcast to discuss the findings in greater detail. This announcement will provide valuable information for individual investors, potentially influencing investment decisions. Additionally, the Company’s progress in developing targeted radiotherapeutics for CNS cancers could have broader implications for the pharmaceutical industry and healthcare sector, driving innovation and potentially improving patient outcomes. Stay tuned for further updates and developments from Plus Therapeutics.
